|
|
Upfront Briefing
Well, that was quick. Two days after the FT put AstraZeneca and Bristol Myers in talks over a roughly $400B combination, Reuters reported Wednesday that no discussions are ongoing. Pascal Soriot gets to keep the best-in-class pipeline that analysts spent Monday insisting he had no reason to dilute, and BMS goes back to being a patent cliff with a cell therapy franchise attached. The FDA had a busier evening. Moderna finally got mFlusiva across as the first licensed mRNA flu shot, six months after the agency refused to even read the application, and Takeda landed Orzeyful in narcolepsy type 1. Neither fully clears: Moderna’s 65-plus label is conditional and Takeda needs the DEA before it can sell a single pill. Meanwhile two biotechs priced upsized IPOs in 24 hours, which is the most cheerful sentence we have written all week.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,723.5 |
(0.2%) |
12.6% |
| Nasdaq 100 |
29,487.8 |
(0.8%) |
17.0% |
| Russell 2000 |
3,019.2 |
(0.6%) |
20.4% |
| Healthcare (XLV) |
164.2 |
1.3% |
5.6% |
| Biotech (XBI) |
153.0 |
0.7% |
25.9% |
| Nasdaq Biotech (NBI) |
6,630.9 |
0.8% |
16.2% |
| Clinical Trials (BBC) |
51.2 |
0.2% |
36.0% |
|
- Healthcare outperformed on earnings rather than headlines: Lilly closed up 3.7% after Q2 adjusted EPS of $8.38 against $6.01 consensus and a full-year revenue guide lifted to $85–87B, with Amgen adding roughly 4.6% on its own raise. XLV gained 1.27% and XBI 0.74%. The Moderna and Takeda approvals both crossed after the cash close.
- The broad tape split: the Dow set a record 54,349 while the Nasdaq 100 gave back 0.83% on a 4.6% slide in Alphabet, as crude extended its decline after Iran said it had reached agreement with Oman on a Strait of Hormuz shipping route, pulling Treasury yields down alongside it.
- Market data: U.S. cash close Wednesday, 5 August 2026.
The Big 3
|
1
|
Reuters: no AstraZeneca-Bristol Myers talks ongoing
|
- Reuters reported Wednesday that no merger discussions are ongoing between AstraZeneca and Bristol Myers Squibb, two days after the Financial Times reported the pair had held talks over recent months on a combination worth roughly $400B. Neither company has confirmed or denied the original report.
- Why it matters: Monday priced this as an acquirer being punished — AZN off as much as 7.8% in London, BMY up nearly 4% in New York. That spread now unwinds, and the read-through is that Soriot keeps a pipeline Jefferies called one nobody needs financial engineering to fix, against an $80B 2030 sales target. The structural objection was always Imfinzi next to Opdivo, two checkpoint franchises under one roof and squarely inside the FTC’s 2023 guidelines. Watch BMS instead: 69% US revenue exposure, a Revlimid cliff and no partner, which puts it back in the market as a buyer of mid-cap oncology rather than a seller of itself.
- Source: Fierce Pharma
- More: CNBC; Endpoints
|
|
2
|
Two FDA approvals land, neither one fully clears
|
- The FDA approved Moderna’s mFlusiva (mRNA-1010) in adults 50 and older, the first licensed mRNA flu shot, on efficacy running about 27% above a standard shot across 40,805 patients; hours earlier it cleared Takeda’s Orzeyful (oveporexton), a first-in-class oral OX2R agonist, for narcolepsy type 1 on the FirstLight and RadiantLight Phase 3s.
- Why it matters: Neither is as clean as the headline. Moderna’s 50–64 cohort got traditional approval; the 65-plus group, where the revenue sits, came through accelerated approval contingent on a confirmatory postmarketing trial — February’s refusal-to-file objection is now a condition rather than a settled question. Takeda cannot ship Orzeyful until the DEA finishes scheduling, putting the launch curve on a regulator’s clock. What both buy is position: Moderna gets a fourth US product and a pandemic-strain manufacturing argument against a standing HHS overhang, Takeda gets first-mover proof for an orexin franchise with TAK-360 behind it and Alkermes and Centessa running at the same target.
- Source: STAT
- More: Fierce Pharma; Takeda; Psychiatric Times
|
|
3
|
Two upsized biotech IPOs price in 24 hours
|
- Braveheart priced an upsized 21,250,000 shares at $18.00 for roughly $382.5M to take Hengrui-licensed cardiac myosin inhibitor BHB-1893 into global Phase 3, listing as BRVE; Attovia priced 17,000,000 shares at $17.00 for $289.0M to fund anti-IL-31 lead ATTO-1310, and began trading Wednesday as ATTO.
- Why it matters: Braveheart is the 17th drug developer to list in 2026 and the second cardiac name built on a Chinese asset. It paid Hengrui $32.5M cash plus an equal slug of stock for ex-Greater China rights against just over $1B in milestones, and every trial to date was designed and run by Hengrui — a 2024-incorporated company with no independent execution record now walking BHB-1893 into Camzyos and Cytokinetics’ Myqorzo on a dosing-convenience argument. Attovia is the cleaner comp at $289M with Phase 1b itch data and a Q3 dosing interval against Galderma’s monthly Nemluvio. Both upsized. The window is open specifically for de-risked assets somebody else paid to de-risk.
- Source: Endpoints
- More: BioPharma Dive; Fierce Biotech
|
Everything Else that broke
- Revolution Medicines raised 2026 spending ahead of potential daraxonrasib launches in the U.S. and Europe. — RevMed
- Galibra picked up FDA orphan and rare pediatric tags for its SSADH deficiency gene therapy. — PR
- Innovent dosed the first patient in a pivotal IBI363/TAK-928 plus bevacizumab CRC study in China. — PR
- Lilly extended its injectable GLP-1 lead over Novo, but trailed in oral GLP-1 sales. — BioCentury
- Coherus reported $13.6M in Q2 LOQTORZI revenue, up 15% from Q1. — PR
- PacBio named Mark Van Oene CEO alongside second-quarter results. — PR
- Vaxcyte set VAX-31 Phase 3 adult topline data for Q4 2026 and more results in 1H27. — PR
- Gilead’s HIV prevention franchise cleared $1B in quarterly sales, with analysts pressing on Yeztugo’s growth durability. — Fierce Pharma
- Sanofi halted a Phase 2 trial of SAR445399 in non-cystic fibrosis bronchiectasis, attributing the suspension to strategic business reasons. — Fierce Biotech
- Lilly dropped another gene therapy trial originating from its $1B Prevail Therapeutics acquisition. — Fierce Biotech
- Novo Nordisk’s CEO acknowledged “a couple of setbacks” across CagriSema and ziltivekimab, and said the company is hunting bolt-on deals. — Fierce Biotech
- Emergent BioSolutions eliminated its top R&D role as CEO Joseph Papa executed another restructuring round. — Fierce Biotech
- Icon signed a multi-year collaboration with Anthropic to deploy Claude across its clinical trial operations; terms were not disclosed. — Fierce Biotech
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Evotec and Odyssey teamed up on AI-enabled autoimmune and inflammation discovery. — PR
- Actimed reacquired global rights to S-oxprenolol from Faraday Pharmaceuticals. — PR
- AstraZeneca and CSPC signed a 51-49 biologics manufacturing joint venture in Shijiazhuang, with CSPC contributing the majority of capital and initial output aimed at drug substances for global markets. — Fierce Pharma
VC / Private Financings
- Expedition Therapeutics closed an oversubscribed $115M Series B, backed by Sanofi among others, to push its lead DPP1 inhibitor through Phase 2 in COPD. — Fierce Biotech
IPOs / Follow-Ons
- Braveheart priced an upsized $382.5M IPO at $18.00 to take BHB-1893 into global Phase 3, listing as BRVE (see The Big 3). — PR
- Attovia priced an upsized $289M IPO at $17.00 (17,000,000 shares) and listed on Nasdaq as ATTO, funding anti-IL-31 lead ATTO-1310 (see The Big 3). Morgan Stanley, Leerink, Citi and RBC ran the book. — Fierce Biotech
Academic Corner - A randomized controlled trial found dronabinol significantly reduced nightmare frequency and intensity in PTSD over 10 weeks. — Nature Medicine
- A NEJM case study examined inflammatory symptoms in a 60-year-old woman with stage II triple-negative breast cancer. — NEJM
- NEJM published a perspective on physician suicide and the cultural cost of silence in medical practice. — NEJM
- A small Phase 1 out of Boston Children’s Hospital found fecal transplant raised peanut tolerance sixfold in food-allergic patients. — Fierce Biotech
|
|
See you tomorrow. The DEA, presumably, whenever it gets round to it.
— BioBucks Team
|
|
|
